Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.

Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, Susan L Neuhausen, Stephen Fox, Beth Y Karlan, Gillian Mitchell, Paul James, Darcy L Thull, Kristin K Zorn, Natalie J Carter, Katherine L Nathanson, Susan M Domchek, Timothy R Rebbeck, Susan J Ramus, Robert L Nussbaum, Olufunmilayo I Olopade, Johanna Rantala, Sook-Yee Yoon, Maria A Caligo, Laura Spugnesi, Anders Bojesen, Inge Sokilde Pedersen, Mads Thomassen, Uffe Birk Jensen, Amanda Ewart Toland, Leigha Senter, Irene L Andrulis, Gord Glendon, Peter J Hulick, Evgeny N Imyanitov, Mark H Greene, Phuong L Mai, Christian F Singer, Christine Rappaport-Fuerhauser, Gero Kramer, Joseph Vijai, Kenneth Offit, Mark Robson, Anne Lincoln, Lauren Jacobs, Eva Machackova, Lenka Foretova, Marie Navratilova, Petra Vasickova, Fergus J Couch, Emily Hallberg, Kathryn J Ruddy, Priyanka Sharma, Sung-Won Kim, Manuel R Teixeira, Pedro Pinto, Marco Montagna, Laura Matricardi, Adalgeir Arason, Oskar Th Johannsson, Rosa B Barkardottir, Anna Jakubowska, Jan Lubinski, Angel Izquierdo, Miguel Angel Pujana, Judith Balmaña, Orland Diez, Gabriella Ivady, Janos Papp, Edith Olah, Ava Kwong, Heli Nevanlinna, Kristiina Aittomäki, Pedro Perez Segura, Trinidad Caldes, Tom Van Maerken, Bruce Poppe, Kathleen B M Claes, Claudine Isaacs, Camille Elan, Christine Lasset, Dominique Stoppa-Lyonnet, Laure Barjhoux, Muriel Belotti, Alfons Meindl, Andrea Gehrig, Christian Sutter, Christoph Engel, Dieter Niederacher, Doris Steinemann, Eric Hahnen, Karin Kast, Norbert Arnold, Raymonda Varon-Mateeva, Dorothea Wand, Andrew K Godwin, D Gareth Evans, Debra Frost, Jo Perkins, Julian Adlard, Louise Izatt, Radka Platte, Ros Eeles, Steve Ellis, Ute Hamann, Judy Garber, Florentia Fostira, George Fountzilas, Barbara Pasini, Giuseppe Giannini, Piera Rizzolo, Antonio Russo, Laura Cortesi, Laura Papi, Liliana Varesco, Domenico Palli, Ines Zanna, Antonella Savarese, Paolo Radice, Siranoush Manoukian, Bernard Peissel, Monica Barile, Bernardo Bonanni, Alessandra Viel, Valeria Pensotti, Stefania Tommasi, Paolo Peterlongo, Jeffrey N Weitzel, Ana Osorio, Javier Benitez, Lesley McGuffog, Sue Healey, Anne-Marie Gerdes, Bent Ejlertsen, Thomas V O Hansen, Linda Steele, Yuan Chun Ding, Nadine Tung, Ramunas Janavicius, David E Goldgar, Saundra S Buys, Mary B Daly, Anita Bane, Mary Beth Terry, Esther M John, Melissa Southey, Douglas F Easton, Georgia Chenevix-Trench, Antonis C Antoniou, Laura Ottini

Journal: Breast cancer research : BCR 2016;18(1):15

PMID: 26857456

Abstract

BACKGROUND

BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).

METHODS

We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.

RESULTS

Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)).

CONCLUSIONS

On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

Address: Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. [email protected].; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. [email protected].; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. [email protected].; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. [email protected].; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. [email protected].; Peter MacCallum Cancer Institute, East Melbourne, Australia. [email protected].; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. [email protected].; Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia. [email protected].; Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia. [email protected].; Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia. [email protected].; Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia. [email protected].; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. [email protected].; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. [email protected].; UPMC Cancer Center, Pittsburgh, PA, USA. [email protected].; Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA. [email protected].; Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA. [email protected].; Department of Epidemiology and Biostatistics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. [email protected].; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA. [email protected].; Department of Medicine and Genetics, University of California, San Francisco, San Francisco, CA, USA. [email protected].; Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, IL, USA. [email protected].; Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. [email protected].; Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia. [email protected].; University Malaya Cancer Research Institute, Faculty of Medicine, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia. [email protected].; Section of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy. [email protected].; Section of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy. [email protected].; Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark. [email protected].; Section of Molecular Diagnostics, Department of Biochemistry, Aalborg University Hospital, Aalborg, Denmark. [email protected].; Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark. [email protected].; Department of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark. [email protected].; Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine, The Ohio State University, Columbus, OH, USA. [email protected].; Division of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. [email protected].; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. [email protected].; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. [email protected].; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. [email protected].; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. [email protected].; Center for Medical Genetics, North Shore University Health System, Evanston, IL, USA. [email protected].; N.N. Petrov Institute of Oncology, St. Petersburg, Russia. [email protected].; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. [email protected].; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. [email protected].; Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. [email protected].; Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. [email protected].; Department of Urology, Medical University of Vienna, Vienna, Austria. [email protected].; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [email protected].; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [email protected].; Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [email protected].; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [email protected].; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [email protected].; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. [email protected].; Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic. [email protected].; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. [email protected].; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. [email protected].; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. [email protected].; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. [email protected].; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. [email protected].; Department of Oncology, Mayo Clinic, Rochester, MN, USA. [email protected].; Department of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA. [email protected].; Department of Surgery, Daerim St. Mary's Hospital, Seoul, Korea. [email protected].; Department of Genetics, Portuguese Institute of Oncology, Porto, Portugal. [email protected].; Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal. [email protected].; Department of Genetics, Portuguese Institute of Oncology, Porto, Portugal. [email protected].; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS (Scientific Institute of Hospitalization and Care), Padua, Italy. [email protected].; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS (Scientific Institute of Hospitalization and Care), Padua, Italy. [email protected].; Department of Pathology, Landspitali University Hospital and Biomedical Centre (BMC), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. [email protected].; Department of Oncology, Landspitali University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland. [email protected].; Department of Pathology, Landspitali University Hospital and Biomedical Centre (BMC), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. [email protected].; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. [email protected].; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. [email protected].; Genetic Counseling Unit, Hereditary Cancer Program, Biomedical Research Institute of Girona (IDIBGI), Catalan Institute of Oncology, Girona, Spain. [email protected].; Breast Cancer and Systems Biology Unit, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Barcelona, Spain. [email protected].; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. [email protected].; Oncogenetics Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and Universitat Autònoma de Barcelona, Barcelona, Spain. [email protected].; Department of Pathology, National Institute of Oncology, Budapest, Hungary. [email protected].; Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. [email protected].; Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. [email protected].; The Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, China. [email protected].; Department of Surgery, The University of Hong Kong, Hong Kong, China. [email protected].; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. [email protected].; Department of Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. [email protected].; Department of Oncology, San Carlos Clinical Hospital Health Research Institute (IdISSC), San Carlos Clinical Hospital, Madrid, Spain. [email protected].; Molecular Oncology Laboratory, San Carlos Clinical Hospital Health Research Institute (IdISSC), San Carlos Clinical Hospital, Madrid, Spain. [email protected].; Center for Medical Genetics, Ghent University, Ghent, Belgium. [email protected].; Center for Medical Genetics, Ghent University, Ghent, Belgium. [email protected].; Center for Medical Genetics, Ghent University, Ghent, Belgium. [email protected].; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. [email protected].; Department of Tumour Biology, Institut Curie, Paris, France. [email protected].; CNRS UMR5558, Université Lyon 1, Lyon, France. [email protected].; Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France. [email protected].; Department of Tumour Biology, Institut Curie, Paris, France. [email protected].; Université Paris Descartes, Sorbonne Paris Cité, Paris, France. [email protected].; INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université Lyon, Lyon, France. [email protected].; Department of Tumour Biology, Institut Curie, Paris, France. [email protected].; Department of Gynaecology and Obstetrics, Technical University of Munich, Munich, Germany. [email protected].; Institute of Human Genetics, University of Wurzburg, Wurzburg, Germany. [email protected].; Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany. [email protected].; Institute for Medical Informatics, Statistics and Epidemiology University of Leipzig, Leipzig, Germany. [email protected].; University of Dusseldorf, Dusseldorf, Germany. [email protected].; Hannover Medical School, Hannover, Germany. [email protected].; Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany. [email protected].; Department of Gynecology and Obstetrics, Technical University of Dresden, Dresden, Germany. [email protected].; Department of Gynaecolgy and Obstetrics, University Hospital of Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany. [email protected].; Institute of Human Genetics, Charité, Berlin, Germany. [email protected].; Institute of Human Genetics, Leipzig, Germany. [email protected].; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA. [email protected].; Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. [email protected].; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. [email protected].; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. [email protected].; Yorkshire Regional Genetics Service, Leeds, UK. [email protected].; Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, UK. [email protected].; Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. [email protected].; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. [email protected].; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. [email protected].; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. [email protected].; Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].; Molecular Diagnostics Laboratory, Institute of Nuclear and Radiological Sciences and Technology (INRASTES), National Centre for Scientific Research "Demokritos", Aghia Paraskevi Attikis, Athens, Greece. [email protected].; Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. [email protected].; Department of Medical Science, University of Turin, Turin, Italy. [email protected].; AO Città della Salute e della Scienza, Turin, Italy. [email protected].; Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. [email protected].; Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. [email protected].; Section of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy. [email protected].; Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy. [email protected].; Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. [email protected].; Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, IRCCS (Scientific Institute of Hospitalization and Care), AOU San Martino - IST National Institute for Cancer Research, Genoa, Italy. [email protected].; Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. [email protected].; Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. [email protected].; Unit of Genetic Counselling, Medical Oncology Department, Regina Elena National Cancer Institute, Rome, Italy. [email protected].; Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), 20133, Milan, Italy. [email protected].; Unit of Medical Genetics, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), Milan, Italy. [email protected].; Unit of Medical Genetics, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), Milan, Italy. [email protected].; Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO), Milan, Italy. [email protected].; Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO), Milan, Italy. [email protected].; Division of Experimental Oncology, CRO Aviano National Cancer Institute, Aviano, PN, Italy. [email protected].; IFOM, FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy. [email protected].; Cogentech Cancer Genetic Test Laboratory, Milan, Italy. [email protected].; National Cancer Institute "Giovanni Paolo II", Bari, Italy. [email protected].; IFOM, FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy. [email protected].; Clinical Cancer Genetics, City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA. [email protected].; Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain. [email protected].; Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain. [email protected].; Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain. [email protected].; Human Genetics Group, Spanish National Cancer Centre (CNIO), Madrid, Spain. [email protected].; Human Genotyping (CEGEN) Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. [email protected].; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. [email protected].; Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia. [email protected].; Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. [email protected].; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. [email protected].; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. [email protected].; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. [email protected].; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. [email protected].; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. [email protected].; State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania. [email protected].; Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. [email protected].; Department of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. [email protected].; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA. [email protected].; Department of Pathology & Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada. [email protected].; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. [email protected].; Department of Epidemiology, Cancer Prevention Institute of California, Fremont, CA, USA. [email protected].; Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Australia. [email protected].; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. [email protected].; Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia. [email protected].; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. [email protected].; Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.